Dimerix Limited announced new data related to the simultaneous use of Dimerix' lead compound DMX-200 (a Phase 3 CCR2 inhibitor) with other compounds in development, such as sparsentan (a Phase 3 dual endothelin and angiotensin receptor blocker) and atrasentan (a Phase 2 endothelin receptor blocker). These in-vitro study data show that the addition of a CCR2 receptor inhibitor such as DMX-200 alongside sparsentan, provided a significantly greater inhibition of key receptor activation in human kidney cells than either compound alone. DMX-200 as an adjunct to an angiotensin receptor blocker: Dimerix is developing DMX-200 for the treatment of kidney diseases and respiratory diseases given to patients already taking an angiotensin receptor blocker (ARB). Previous studies conducted by Dimerix have shown that simultaneous blockade of these receptors causes complete signal interference of key receptors implicated in a range of inflammatory diseases such as chronic kidney disease and respiratory disease. D imerix has previously generated and published data to support the need to inhibit both CCR2 and angiotensin II type 1 (AT1R) receptors at the same time to fully stop signalling of either receptor, which is further supported by consistent clinical data in patients with various chronic kidney diseases. Dimerix has now confirmed that the blockade of AT1R by sparsentan is indistinguishable from other ARBs in its ability to prevent hyperactivation of CCR2 in the presence of AT1R. This data indicates that sparsentan could be used as an alternative to an ARB, such as irbesartan, as the adjunct therapy with DMX-200. DMX-200 as an adjunct to an endothelin receptor blocker: Dimerix has now also discovered new evidence of a functional interaction between endothelin A receptor (ETAR) and CCR2 receptors, whereby Dimerix determined that simultaneous inhibition of CCR2 and ETAR is required to fully stop signalling of these receptors. These data suggest that Dimerix' lead CCR2 inhibiting compound, DMX-200, may have a strongly beneficial effect for patients receiving new compounds in clinical development such as the endothelin receptor antagonist atrasentan, or the dual angiotensin receptor blocker and endothelin receptor antagonist, sparsentan. Sparsentan is a novel small-molecule candidate in Phase 3 development by Travere Therapeutics for the treatment of focal segmental glomerulosclerosis (FSGS). Sparsentan is a single molecule designed to selectively block both the ETAR and AT1R involved in progression of kidney diseases. In February 2021, Travere reported positive interim data for its Phase 3 study in FSGS patients, whereby 16% more patients achieved a proteinuria reduction of 40% on sparsentan compared to irbesartan (29% of patients demonstrated 40% reduction in proteinuria on DMX-200 compared to placebo (irbesartan alone) in the Dimerix Phase 2 study reported in July 2020). Potential benefit to patients: This new data clearly demonstrates that DMX-200 has the potential to provide greater potency andefficacy for compounds such as sparsentan and atrasentan that could result in further tangible therapeutic advantage for patients suffering from kidney disease, such as focal segmental glomerulosclerosis (FSGS). As a result of this surprising data demonstrating a coupling between CCR2 and an endothelin receptor, Dimerix has completed a key step in securing ownership over the benefits of DMX-200 by lodging a provisional patent application. The new Australian provisional patent application, titled "Treatment of Inflammatory Diseases" with filing number 2021900862, has a priority date of 23 March 2021 and if granted would expire post 2042. This new patent filing further supports DMX-200, enhancing the strong competitive position.